Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CSL Behring

Division of CSL Ltd.
www.cslbehring.com

Latest From CSL Behring

Korean Biotech Sentiment Still Shaky But IPO Recovery Seen By Year-End

After a lackluster year so far for South Korean biotech IPOs amid disappointing clinical trial news, investor interest is beginning to pick up, with several companies that have been under the spotlight slated to debut on the market in the coming months.
South Korea Financing

England's NICE OKs Shire’s Takhzyro For Rare Hereditary Disease

England’s health technology assessment body has recommended the use of Shire’s orphan drug Takhzyro for use in patients with hereditary angioedema, but only in certain circumstances and provided the company offers the product at the agreed discounted price.

United Kingdom Health Technology Assessment

Mustang Bio Joins RMAT List; Eiger Brings Home Its 4th BTD

Gene therapy and lambda interferon products are highlighted in the new Review Pathways section of the US FDA Performance Tracker, which keeps track of breakthrough therapy (BTD), regenerative medicine advanced therapy (RMAT), qualified infectious disease product (QIDP) designations and biosimilar submissions.

Rare Diseases Review Pathway

Grifols Wins Early FDA OK For SCIg Xembify, Setting Stage For Margin Growth

Analysts said Grifols is poised for profit margin growth after the US FDA approved its first 20% subcutaneous immunoglobulin, Xembify, for treating primary immunodeficiencies.

Commercial Companies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • ZLB Central Laboratory
  • ZLB Bioplasma AG
  • ZLB Behring
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • CSL Ltd.
  • Senior Management
  • Paul Perreault, CEO
    David Lamont, CFO
    Andrew Cuthbertson, PhD, Dir., R&D & CSO
    Alan Wills, SVP, Strategy & Bus. Dev.
  • Contact Info
  • CSL Behring
    Phone: (41)(610) 878-4000
    1020 First Ave.
    P.O. Box 61501 King of Prussia, PA 19406-0901
    USA
UsernamePublicRestriction

Register